AAPP Scientific Poster Session Abstracts

A Harm Reduction Approach to Overdose Recognition and Naloxone Training in an FQHC Serving Unhoused Individuals Education/Training/Stigma Harm Reduction Opioid Use Disorder Substance Use Disorders

A Pharmacist-Led Initiative to Improve Stimulant Monitoring Compliance in Patients at A Veteran Affairs Healthcare System Monitoring Stimulants VA

A Randomized Crossover Study Evaluating Dose Proportionality of a Novel Lithium Carbonate Extended-Release (XR) 600 mg and 900 mg Bi-Layer Matrix Formulation Under Fed Conditions in Healthy Adults Bipolar Disorder Mood Stabilizers Lithium Carbonate Clinical Trial Pharmacokinetics Dose Proportionality Novel Formulation

A Randomized, Three-Way Crossover Study Evaluating the Bioavailability of a Novel Single Dose QD Lithium Carbonate XR Bi-Layer Matrix Formulation Compared With BID and TID Lithium Regimens in Healthy Adult Volunteers Under Fed Conditions Bipolar Disorder Mood Stabilizers Lithium Carbonate Clinical Trial Pharmacokinetics Bioavailability Novel Formulation

A Randomized, Two-Way Crossover Study Evaluating the Steady-State Bioequivalence of a Novel QD Lithium Carbonate XR 900 mg Bi-Layer Matrix Formulation Compared With BID Lithium Carbonate XR 450 mg Formulation in Healthy Adults Under Fed Conditions Bipolar Disorder Mood Stabilizers Lithium Carbonate Clinical Trial Pharmacokinetics Bioequivalence Novel Formulation

A Retrospective Evaluation on the Appropriate Use, Safety, and Clinical Outcomes of Subcutaneous Risperidone Extended-release Injectable Suspension Compared to Intramuscular Paliperidone Palmitate Adherence Antipsychotics Bipolar Disorder Long-Acting Injectable Schizophrenia Suicide Transitions Of Care

A Secondary Analysis of the Relationship Between Cocaine Craving and Depression Long-Acting Injectable Major Depression Stimulants Substance Use Disorders Cocaine Use Disorder Beck Depression Inventory Cocaine Craving Buprenorphine/ Naloxone Naltrexone

A Subanalysis From a Study Assessing the Interaction Between Lithium and GLP-1 Receptor Agonists: A Case Level Assessment of Lithium Toxicity Bipolar Disorder Drug-Drug Interactions Therapeutic Drug Monitoring

Addressing Psychiatric Mental Health Disparities Using an Interprofessional Practice Approach Education/Training/Stigma Health Equity Transitions Of Care Interprofessional Practice Psychiatric Mental Health Practice

Adherence to Laboratory Monitoring Protocols for Mood Stabilizers in an Inpatient Psychiatric State Hospital Adherence Monitoring Therapeutic Drug Monitoring

Adherence to Metabolic Syndrome Monitoring Guidelines in Veterans Receiving Long-Acting Injectable Antipsychotics: A Retrospective Chart Review Antipsychotics Long-Acting Injectable Monitoring Schizophrenia VA

Adjunctive Lumateperone in Patients With Major Depressive Disorder and Anxious Distress Bipolar Disorder Schizophrenia

Administration Patterns of Paliperidone Long-Acting Injectables: A Retrospective Analysis in Minnesota Behavioral Health Pharmacies Adherence Antipsychotics Bipolar Disorder Long-Acting Injectable Monitoring Schizophrenia Formulations Persistence Missed Dose Gap In Therapy Pharmacokinetics

An Evaluation of Clozapine – Associated Myocarditis Monitoring Order Set Implementation Antipsychotics Monitoring Schizophrenia

An Evaluation of Over-the-Counter Supplement Use, Documentation, and Clinician Engagement in an Outpatient Behavioral Health Clinic Adherence Drug-Drug Interactions Education/Training/Stigma Monitoring Sleep Disorder Supplements Herbal Products Over The Counter Weight Management Stress Management

Antipsychotic Stewardship in an Outpatient Mental Health Clinic Within the Veterans Health Administration Antipsychotics Bipolar Disorder Harm Reduction Monitoring Schizophrenia VA Stewardship Quality Improvement

Anxiolytic Effects of Dextromethorphan-Bupropion (45mg/105mg): Post Hoc Analyses Across Trials in Major Depressive Disorder Antidepressants Anxiolytics Major Depression

Appropriateness of Metabolic Monitoring for High-Risk Second-Generation Antipsychotics Antipsychotics Monitoring Psychotropic Stewardship

Assessing Appropriate Transitions of Care for Patients with Alcohol Use Disorders Alcohol Use Disorder Monitoring Substance Use Disorders Transitions Of Care VA

Assessing Clinical Pharmacists’ Perspective on Clozapine REMS Removal Antipsychotics Health Equity Monitoring Schizophrenia Therapeutic Drug Monitoring Clozapine REMS Policy Change

Assessing the Effectiveness of an Interprofessional Education Program for Reducing Health Professions Student Stigma of Formerly Incarcerated Individuals Education/Training/Stigma Health Equity

Assessing the Impact of Pharmacist-Led Education on Veterans’ Acceptance of Alcohol Use Disorder or Opioid Use Disorder Services Alcohol Use Disorder Opioid Use Disorder Substance Use Disorders

Assessing the Management of Medetomidine Intoxication and Withdrawal: A Literature Review Opioid Use Disorder Substance Use Disorders Medetomidine

Assessment of Facility Compliance with Absolute Neutrophil Count (ANC) Monitoring Before and After Elimination of the FDA Clozapine REMS Program Antipsychotics Major Depression Monitoring Schizophrenia VA

Assessment of the Impact of an Inpatient Clinical Pharmacist Practitioner Consult Service for Medication for Alcohol Use Disorder Alcohol Use Disorder Substance Use Disorders VA

Assessment of Therapeutic Outcomes of Buprenorphine Micro-Induction Adherence Harm Reduction Monitoring Opioid Use Disorder Substance Use Disorders

Association Between AAPP Student Chapter Membership and Pursuit of Psychiatric Pharmacy Residency Training Education/Training/Stigma AAPP Student Organization PGY2 Psychiatric Residency

Association of Long-Acting Injectable (LAI) Medication Adherence and Distance to a Facility in an Urban Healthcare System Alcohol Use Disorder Antipsychotics Health Equity Long-Acting Injectable Schizophrenia Transitions Of Care VA

Barriers to Accessing Mental Health Resources Among Graduate Students in Medical Programs: A Cross-Sectional Survey Mental Health Resources Barriers To Care Burnout Graduate Students

Beyond Stimulants: Antidepressants for Pediatric Attention-Deficit/Hyperactivity Disorder- Efficacy and Safety Antidepressants Child And Adolescent Psychiatry Harm Reduction Stimulants

Beyond the Books: Measuring Effects of a Wellness Program on Pharmacy Students' Well-being Education/Training/Stigma Wellness Professional Efficacy Intervention

Bridging Care with Pharmacy Students in Pharmacist-Led Long-Acting Injectable Antipsychotic Transitions Education/Training/Stigma Long-Acting Injectable Transitions Of Care Care Coordination

Bridging the Gap in Clozapine Re-titration Practices and Outcomes Following Brief Interruption Antipsychotics Schizophrenia Clozapine Retitration

Buprenorphine for Kratom Use Disorder in a Veteran Population: A Case Series and Literature Review Substance Use Disorders VA Kratom Use Disorder Buprenorphine

Burnout and Well-Being Among Pharmacy Technicians across a Hospital System Health Equity Pharmacy Technician Wellness Burnout

Characterization of Adjunctive Antipsychotic Therapy in the Treatment of Depressive Disorders in Older Adults Antipsychotics Geriatrics Major Depression

Characterization of Discharge Insulin Regimens at an Inpatient Psychiatric Hospital Adherence Bipolar Disorder Monitoring Schizophrenia Insulin Diabetes

Clinical and Economic Impact of Hospital Inpatient Free Trial Program Participation at a Start Up Behavioral Health Hospital During Opening Year Antipsychotics Long-Acting Injectable Schizophrenia Readmission Cost

Clinical Outcomes of GLP-1 Receptor Agonists FDA-Approved for Weight Management in Patients with Binge Eating Disorder: A Systematic Review Eating Disorders Obesity Glucagon-Like Peptide 1 Receptor Agonists

COMP 005 and COMP 006: Approaches to Challenges in Randomized-Controlled Clinical Trials with Psychedelics Antidepressants Major Depression

Comparative Effects of Risperidone Extended-Release Subcutaneous Injection Versus Paliperidone Palmitate Intramuscular Injection on Patient Outcomes Post Discharge Antipsychotics Long-Acting Injectable Transitions Of Care

Comparing Outcomes of Long-Acting Injectable Antipsychotic Formulations Among Veterans Adherence Antipsychotics Bipolar Disorder Long-Acting Injectable Schizophrenia VA

Comparing the Impact of Tetrahydrocannabinol (THC) on 30-day Readmission Rates and Hospital Length of Stay in Patients with Depression Antidepressants Major Depression Cannabis

Comparison of Clinical Outcomes Between Subcutaneous and Intramuscular Long-Acting Injectable Antipsychotics in the Outpatient Setting Adherence Antipsychotics Bipolar Disorder Long-Acting Injectable Schizophrenia

Comparison of Long-acting Injectable Risperidone Products Adherence Antipsychotics Long-Acting Injectable Schizophrenia

Comparison of Outcomes Among D2 Receptor Partial Agonists for Augmentation in Major Depressive Disorder Antidepressants Antipsychotics Major Depression

Comparison of Parenteral Lorazepam vs Midazolam in Combination with Antipsychotics for Acute Agitation in Pediatric Patients Acute Agitation Children/Adolescents Benzodiazepine

Compulsive Sexual Behavior Management Without Anti-androgens: SSRI and PRN Use in a State Psychiatric Hospital Acute Agitation Compulsive Sexual Behavior Selective Serotonin Reuptake Inhibitors Inpatient Psychiatry PRN Medication Use

Continuity of Long Acting Injectable Antipsychotics Adherence Antipsychotics Long-Acting Injectable

Creation of a Pharmacotherapy Laboratory Experience for Long-Acting Injectable Antipsychotic Medications Given by Gluteal Administration Antipsychotics Education/Training/Stigma Long-Acting Injectable

Crystal Clear Guidance on Recognizing and Managing Methamphetamine-Induced Psychosis Antipsychotics Stimulants Substance Use Disorders Methamphetamine-Induced Psychosis

Describing the Role of a Board-Certified Psychiatric Pharmacist in a Community-Based First Episode Psychosis Clinic Long-Acting Injectable Monitoring Coordinated Specialty Care First Episode Psychosis

Development and Application of PBPK Models for Cariprazine and Its Active Metabolites to Predict CYP3A-Mediated Drug-Drug Interactions and Inform Dose Adjustment Strategies Antipsychotics Bipolar Disorder Drug-Drug Interactions Major Depression Schizophrenia Pharmacokinetic Modeling Dose Recommendations

Diagnosis and Treatment of Anxiety or Depression Following Clostridioides difficile Infection Antidepressants Anxiolytics Major Depression Clostridioides Difficile Infection Microbiome Gut Brain Axis

Difference in Length of Hospitalization between Risperidone Extended-Release Injection vs. Paliperidone Palmitate Antipsychotics Long-Acting Injectable Schizophrenia Risperidone Paliperidone Palmitate

Don't Be Rash! Safety of Lamotrigine Rapid Titrations Bipolar Disorder Harm Reduction Monitoring Neurology VA

Dosing to Effect With Weekly and Monthly Subcutaneous Buprenorphine: Post Hoc Analysis of a Phase 3, Open-label Study Long-Acting Injectable Opioid Use Disorder

Droperidol versus Haloperidol for Severe Agitation in the Emergency Department Acute Agitation Antipsychotics Emergency Department

Effect of Pharmacy Student Graduation and Residency Rates on Subsequent Board Certification Rates Education/Training/Stigma Board Certification

Effects of a Curricular Long Acting Injectable (LAI) Antipsychotic Workshop on Student Pharmacists’ Readiness and Confidence to Administer LAIs Antipsychotics Long-Acting Injectable

Effects of High Sensory-Processing Sensitivity On Stress Levels And Academic Performance of College Students Education/Training/Stigma Sensory Processing Sensitivity Stress Female Gender Academic Performance

Efficacy and Sleep Outcomes of Viloxazine Extended-Release in a Decentralized Trial of Adults with ADHD and Mood Symptoms based on Self-Reported Cannabis Use ADHD Cannabis Use

Elinzanetant as a Dual Neurokinin-1/3 Receptor Antagonist in Menopausal Vasomotor Symptom Management: A Scoping Review Menopausal Vasomotor Symptoms

Empagliflozin and False Positive for Ethanol on Urine Toxicology: a Case Report Alcohol Use Disorder Drug-Drug Interactions Monitoring Therapeutic Drug Monitoring VA Urine Drug Screen

EMPOWERing (Eliminating Medications through Patient OWnership of End Results) Change: A Strategic Approach to Deprescribing Benzodiazepines Anxiolytics Geriatrics VA Deprescribing Medication Safety

Enhancing Measurement Based Care Through Mental Health Interdisciplinary Team Collaboration Monitoring VA Measurement Based Care Collaboration Interdisciplinary Team Patient Reported Outcome Measures

Establishing a Free Valproic Acid (VPA) Therapeutic Range for Affective Disorders: A Retrospective Analysis Bipolar Disorder Monitoring Substance Use Disorders Therapeutic Drug Monitoring Mood Stabilizers

Establishment of a Pharmacist-Integrated Opioid Use Disorder Service Adherence Education/Training/Stigma Opioid Use Disorder Substance Use Disorders Therapeutic Drug Monitoring

Evaluating Clozapine Monitoring After The Removal of Risk Evaluation and Mitigation Strategies (REMS) Antipsychotics Monitoring Schizophrenia

Evaluating Secure Messaging as a Tool for Alcohol Use Disorder (AUD) Pharmacotherapy Outreach in Patients with Elevated Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) Scores Alcohol Use Disorder Secure Messaging

Evaluating the Evidence of Glucagon-Like Peptide-1 Receptor Agonists on Neurocognition Neurology Neurocognitive Disorder Glucagon-Like Peptide-1 Receptor Agonists

Evaluating the Impact of DEA-Licensed Clinical Pharmacist Practitioners on Prescribing Practice of Buprenorphine in Veterans Opioid Use Disorder Substance Use Disorders VA

Evaluating the Relationship Between Anticholinergic Cognitive Burden and Antipsychotic Burden in Patients With Schizophrenia or Schizoaffective Disorder Admitted To an Inpatient Psychiatric Hospital Antipsychotics Monitoring Schizophrenia

Evaluating the Safety of Coadministration of Intramuscular Olanzapine and Benzodiazepines for Agitation in the Emergency Department Acute Agitation Antipsychotics Anxiolytics Drug-Drug Interactions Monitoring

Evaluating Time to Competency with Antipsychotic Strategies in Treatment-Resistant Schizophrenia at Forensic Psychiatric Facility Antipsychotics Long-Acting Injectable Schizophrenia Treatment-Resistant Schizophrenia/ Treatment Refractory Schizoph Clozapine

Evaluation of a clinical pharmacist practitioner’s impact on Veterans Health Administration metrics related to opioid safety through population health dashboard monitoring at a Veteran Affairs Health Care System Opioid Use Disorder VA

Evaluation of a Pharmacist-Led Wraparound Service Delivered Through a Medicaid Organization to Support Post-Discharge Continuity of Long-Acting Injectable Antipsychotics Adherence Long-Acting Injectable Schizophrenia

Evaluation of a Psychiatric Pharmacist–Led Inpatient Lithium Test-Dose Protocol Bipolar Disorder Major Depression Monitoring Therapeutic Drug Monitoring Mood Stabilizers

Evaluation of a Scoring Tool to Identify High-Risk Discharges in Psychiatric Transitions of Care Transitions Of Care Discharge Medication Reconciliation

Evaluation of Appropriate Z-Drug Prescribing and Deprescribing at a Large VA Medical Center Health Equity VA Insomnia Z-Drugs Deprescribing

Evaluation of Implementation of Mental Health Clinical Pharmacist Practitioners in Post Discharge Follow-up after an Inpatient Mental Health Discharge Transitions Of Care VA

Evaluation of laboratory monitoring in patients on antipsychotics using the Psychotropic Drug Safety Initiative (PDSI) database Antipsychotics Monitoring VA

Evaluation of Pharmacist Intervention to Improve Tobacco Use Screening Reminder Completion During Admission to an Inpatient Psychiatric Ward Harm Reduction Monitoring Substance Use Disorders VA

Evaluation of Pharmacist-Led Medication-Assisted Treatment (MAT) Groups in Outpatient Mental Health Clinics Harm Reduction Substance Use Disorders Medication Assisted Treatment MAT Interdisciplinary Model

Evaluation of Sexual Function With Adjunctive Lumateperone in Patients With Major Depressive Disorder Bipolar Disorder Schizophrenia

Evaluation of the Impact of Illness Management and Recovery (IMR) Group Attendance on Medication Adherence in a Forensic Psychiatric Facility Adherence Antipsychotics Bipolar Disorder Education/Training/Stigma Schizophrenia Mood Stabilizers

Evaluation of the Impact of Pharmacogenomics Clinical Decision Support on Psychiatric Medications Antidepressants Pharmacogenomics VA

Evaluation of Viloxazine ER with and without Concomitant Stimulant Use in a Decentralized Trial of Adults with ADHD and Symptoms of Depression and Anxiety ADHD

Expanding Primary Care–Mental Health Integration Through Pharmacist-led Medication Management Across Community-Based Outpatient Clinics Adherence Alcohol Use Disorder Antidepressants Major Depression Post-Traumatic Stress Disorder/ PTSD Sleep Disorder Substance Use Disorders Transitions Of Care VA

Exploring the Relationship between Gen-Z Internet Access and Self Diagnosing of ADHD Education/Training/Stigma Harm Reduction Health Equity Monitoring ADHD

From Post-Transplant Delirium to Neuroleptic Malignant Syndrome: A Case of High-Dose Antipsychotic Exposure Acute Agitation Antipsychotics Delirium

High Dose versus Standard Dose Naltrexone for Alcohol Use Disorder Alcohol Use Disorder Harm Reduction Substance Use Disorders VA

Hypnotic Use in an Adolescent Inpatient Behavioral Facility Child And Adolescent Psychiatry Sleep Disorder Insomnia Hypnotics Poly-Pharmacy

Impact of a Pharmacist-Led Abnormal Involuntary Movement Scale Service Antipsychotics Harm Reduction Neurology Drug Induced Movement Disorders Tardive Dyskinesia

Impact of a Student-Driven Journal Club Initiative for AAPP Collegiate Chapters Education/Training/Stigma Journal Clubs Collegiate Chapter

Impact of an Advanced Psychiatric Pharmacy Elective on Pharmacy Students’ Comfort, Attitudes, and Perceptions Toward Mental Health Conditions Education/Training/Stigma Curriculum

Impact of Antidepressant Use on Bleeding Risk in Patients with Solid Tumor Malignancies Antidepressants Education/Training/Stigma

Impact of Clinical Pharmacists on Cost Avoidance in an Epilepsy Clinic Neurology VA Cost Avoidance Economic Evaluation Seizures

Impact of CYP2D6-Inhibiting Antidepressants on Beta-Blocker Dosing and Safety Outcomes in Heart Failure Antidepressants Drug-Drug Interactions Major Depression CHF

Impact of Implementation of Formulary Preferred Risperidone Extended-Release Injectable Suspension on Prescribing Patterns Adherence Antipsychotics Schizophrenia VA

Impact of Lifetime Substance Use Disorder of Psychiatric Symptoms and Treatment Outcomes for Black Adults Treated with Clozapine Alcohol Use Disorder Antipsychotics Monitoring Opioid Use Disorder Schizophrenia Substance Use Disorders

Impact of Long-Acting Injectable Antipsychotics on 30-day and 90-day Readmission Rates in Adolescent Patients Adherence Antipsychotics Child And Adolescent Psychiatry Long-Acting Injectable Schizophrenia

Impact of Medication Education and Clean Syringe Exchange from Harm Reduction Program Initiated at a VA Healthcare System Education/Training/Stigma Harm Reduction Substance Use Disorders VA Syringe Service Program

Impact of Mental Health First Aid Training on Knowledge and Attitudes in California Pharmacy Professionals Education/Training/Stigma Suicide Prevention Referrals/linkages

Impact of Neurology Botulinum Toxin Note Template on Increasing IncobotulinumtoxinA Use and Reducing OnabotulinumtoxinA Costs Neurology VA

Impact of Oral Overlap During Initiation of Subcutaneous Risperidone Extended-Release Injectable on Clinical and Safety Outcomes Antipsychotics Long-Acting Injectable

Impact of Pharmacist-Driven Chart Reviews on HbA1c and Glucose Monitoring in Veterans on Antipsychotics Antipsychotics Bipolar Disorder Major Depression Monitoring Post-Traumatic Stress Disorder/ PTSD Schizophrenia Therapeutic Drug Monitoring VA

Impact of Tirzepatide on Binge Eating Behaviors: A Case Report Binge Eating Disorder Obesity

Implementation and Evaluation of a Psychiatric Pharmacist-Led Medication for Opioid Use Disorder Clinic in an Underserved Outpatient Setting Opioid Use Disorder Substance Use Disorders

Implementation of a Pharmacist-Led Workflow for Managing Second-Generation Antipsychotic Weight Gain in an Inpatient Psychiatric Facility Antipsychotics Bipolar Disorder Harm Reduction Major Depression Schizophrenia Metformin Antipsychotic Induced Weight Gain Second Generation Antipsychotic Metabolic Risk

Implementation of a Standardized Psychiatric Pharmacist Protocol in an Inpatient Substance Use Disorder Program Alcohol Use Disorder Opioid Use Disorder Substance Use Disorders Practice Expansion Collaborative Drug Therapy Management

Implementation of an Adherence‑Based Contingency Management Program for Long‑Acting Injectable Buprenorphine in Veterans with Opioid Use Disorder Harm Reduction Long-Acting Injectable Opioid Use Disorder Substance Use Disorders VA

Implementation of an Integrated Dashboard and Automation Tool to Monitor Long-Acting Injectable Compliance for Veterans in an Outpatient Setting Adherence Antipsychotics Long-Acting Injectable Substance Use Disorders VA

Implementation of Naloxone Dispensing by Outpatient Clinical Pharmacists at a Rural Medical Facility Education/Training/Stigma Harm Reduction Opioid Use Disorder Stimulants Substance Use Disorders Education/stigma Opioid Overdose Stimulant Use Disorder Substance Use Disorder

Implementing a Pharmacist-Led, Real-Time Clozapine Titration Workflow Using Rapid Therapeutic Drug Monitoring in an Inpatient Psychiatric Hospital Monitoring Schizophrenia Therapeutic Drug Monitoring Clozapine

Improving Interpretation and Follow-up of Unexpected Urine Drug Screen Results in Veterans: A Prospective Chart Review Harm Reduction VA

Improving Teratogenic Extreme Risk Drug Counseling in Veterans of Childbearing Potential Teratogenic Medications

Increasing Access to Naloxone in Patients with Stimulant Use Disorder through AudioCARE System at the South Texas Veterans Health Care System Education/Training/Stigma Health Equity Opioid Use Disorder Stimulants Substance Use Disorders VA Naloxone Overdose

Increasing Access to Pharmacist Services within a Community Detoxification and Crisis Stabilization Facility Alcohol Use Disorder Monitoring Substance Use Disorders Transitions Of Care Detoxification Withdrawal Management Acute Stabilization Pharmacist-Led Interventions Clinical Pharmacy Services

Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia Antipsychotics Long-Acting Injectable Schizophrenia Transitions Of Care Aripiprazole Lauroxil Inpatient Safety

Insomnia Among Pharmacy Students Using the Insomnia Symptom Questionnaire : A Cross-Sectional Survey Analysis Education/Training/Stigma Insomnia Observance Pharmacy Sudents Academia

Integrating clinical pharmacy services into a psychiatric emergency room to improve patient outcomes at a Veterans Affairs Healthcare System Drug-Drug Interactions Monitoring Transitions Of Care VA Psychiatric Emergency Room

Learning about Long-Acting Injectable Antipsychotics (LAI-APs) Through Skills-Based Training Antipsychotics Education/Training/Stigma Long-Acting Injectable Monitoring Schizophrenia

Longitudinal Integration of a Psychiatric Pharmacist into Outpatient Neurology Services for Veterans Neurology VA

Management of Lithium Therapy in Patients Undergoing Electroconvulsive Therapy at an Academic Medical Center Bipolar Disorder Major Depression Therapeutic Drug Monitoring Mood Stabilizers Electroconvulsive Therapy Delirium

Managing Withdrawal from Very High Doses of Non-Prescribed Fentanyl During Low Dose Initiation of Buprenorphine: Pulling all the Stops Opioid Use Disorder Substance Use Disorders Buprenorphine Low Dose Initiation Full-Agonist Opioids

Medication Errors Identified Through Pharmacy-Led Medication Reconciliation in an Inpatient Behavioral Health Facility Transitions Of Care Medication Reconciliation

Medication for Alcohol Use Disorder in Veterans with Co-occurring Alcohol and Opioid Use Disorders Receiving Buprenorphine: A Retrospective Review Adherence Alcohol Use Disorder Opioid Use Disorder Schizophrenia Substance Use Disorders VA Medications For Alcohol Use Disorder Medications For Opioid Use Disorder

Mind Matters: A Student-Led Mental Health Awareness Fair to Reduce Stigma and Promote Psychiatric Pharmacy Psychiatric Pharmacy Education Mental Health Stigma Reduction Student-Led Community Engagement Medication Counseling Strategies Mental Health Advocacy

MiniBites: An Education Platform for Pharmacy Preceptors and Its Impact on Opioid Use Disorder Knowledge and Perceptions – A Pilot Study Education/Training/Stigma Harm Reduction Opioid Use Disorder

Modification of Long-Acting Injectable Antipsychotic Guidelines within an Academic Health System Adherence Long-Acting Injectable

Multi-Site Pilot Evaluation of a Novel, Educational, Interprofessional Board Game, “Journey to Recovery,” as a Teaching and Learning Tool Education/Training/Stigma Opioid Use Disorder

Naltrexone Long-Acting Injectable for Concurrent 'Kratom Use Disorder' and Alcohol Use Disorder Long-Acting Injectable Substance Use Disorders

Needs Assessment for Implementing Pharmacist-Driven Tardive Dyskinesia Monitoring in Pediatric Psychiatric Care Antipsychotics Child And Adolescent Psychiatry Tardive Dyskinesia

No REMS, No Roadmap? Navigating Clozapine Dispensing in Texas Community Pharmacies Antipsychotics Education/Training/Stigma Schizophrenia Clozapine

Olanzapine and Samidorphan in Adults With Schizophrenia or Bipolar I Disorder: Updated Review of Clinical Data Antipsychotics Bipolar Disorder Schizophrenia Mood Stabilizers Olanzapine Olanzapine/Samidorphan Relapse/Retention

Olanzapine Prescribing Practices Pre and Post Olanzapine Alert Implementation on Inpatient Psychiatric Units Antipsychotics Harm Reduction Schizophrenia

Optimizing Phenobarbital Dosing in Obese Patients with Alcohol Withdrawal Syndrome: A Retrospective Evaluation of Actual Versus Ideal Body Weight-Based Strategies Alcohol Use Disorder Harm Reduction Substance Use Disorders Phenobarbital Benzodiazepine

Oral Supplementation of Long-Acting Injectable Second-Generation Antipsychotics in Adults with Serious Mental Illness Antipsychotics Drug-Drug Interactions Harm Reduction Long-Acting Injectable Monitoring Schizophrenia Transitions Of Care

Outcomes of Pharmacist-Initiated Monitoring for Clozapine-Associated Myocarditis in Clozapine Naïve Psychiatrically Hospitalized Patients Antipsychotics Monitoring Schizophrenia

Paranoia Associated with Venlafaxine Discontinuation: A Case Report Antidepressants Major Depression Paranoia Antidepressant Discontinuation

Patient-Reported Quality of Life and Functional Impact in Patients With Symptomatic Remission of Tardive Dyskinesia: Post Hoc Analyses From the Phase 4 KINECT-PRO™ Study Tardive Dyskinesia Patient Reported Outcomes Quality Of Life VMAT-2 Valbenazine

Pharmacist Burnout in North Carolina: A Cross Sectional Study on Prevalence and Contributing Factors Education/Training/Stigma Health Equity Pharmacist Burnout Pharmacy Stressors Professional Well-Being

Pharmacists for Mental Health Equity: A Community Outreach Initiative Education/Training/Stigma Health Equity Marginalized Populations

Pharmacological Management of Substance Use Disorders in the Older Adult Patient: A Narrative Review Alcohol Use Disorder Geriatrics Opioid Use Disorder Stimulants Substance Use Disorders

Pharmacy Student Perceptions of Interprofessional Clinical Education During a Psychiatric Pharmacy Experience Education/Training/Stigma Interprofessional Teamwork Team Based Practice Collaborative Practice

Pharmacy Student Use of Artificial Intelligence (AI) During a Bipolar Disorder Therapeutics Case: Can you “out-smart” AI? Bipolar Disorder Education/Training/Stigma Artificial Intelligence

Piloting MOUD Maintenance Clinical Services in Community Pharmacies: A Hybrid Implementation–Effectiveness Study Opioid Use Disorder Implementation Science

Post-Launch Adverse Events Reported to FDA Adverse Event Reporting System for Long-Acting Injectable Buprenorphine Long-Acting Injectable Opioid Use Disorder

Prescribing Improvements Following Interventions to Reduce Anticholinergic Burden in Older Adults Geriatrics Therapeutic Drug Monitoring Anticholinergic

Primidone-Induced Lumateperone Treatment Failure in a Patient with a History of Bipolar Depression Bipolar Disorder Drug-Drug Interactions Essential Tremor

Promoting Evidence-Based Practices for Opioid Use Disorder: An Evaluation of the TEACH OUD Academic Detailing Initiative Education/Training/Stigma Harm Reduction Opioid Use Disorder

Provider Perspectives on Barriers to Long-Acting Injectables Antipsychotics Health Equity Long-Acting Injectable Provider Perspectives

Psychocardiology of Depression: Evidence-Based Interventions and Clinical Implications in Cardiovascular Disease Antidepressants Drug-Drug Interactions Major Depression Cardiovascular Diseases/arrhythmias Collaborative Care

Psychonephrology Perspective on Psychotropic Medication–Related Nephrotoxicity in Renal Impairment: A Scoping Review Harm Reduction Therapeutic Drug Monitoring Nephrotoxicity Psychotropics

Psychotropic Medications in Psycho-Oncology for the Management of Chemotherapy-Related Cognitive Dysfunction: A Literature Review Antidepressants Harm Reduction Neurology Therapeutic Drug Monitoring Oncology

Psychotropic Prescribing Patterns in Anorexia Nervosa Patients Presenting to an Inpatient Eating Disorders Program Antidepressants Antipsychotics Anorexia Nervosa Eating Disorders

Putting the ‘Person’ in Prescription: The Transformative Power of Lived Experience in Pharmacy Education Education/Training/Stigma Lived Experience Storytelling Patient Panel Reflective Learning Pharmacy Education

Rate of Hyponatremic Events Secondary to Antidepressant Use Within a Veteran Population Antidepressants Major Depression Monitoring Post-Traumatic Stress Disorder/ PTSD VA Hyponatremia

Re-evaluation of Medication Management to Prevent Restraint Episodes in Adult Patients Admitted to an Inpatient Psychiatric Facility Following Quality Improvement Efforts Acute Agitation Antipsychotics Anxiolytics Education/Training/Stigma Therapeutic Drug Monitoring Restraint Quality Improvement Mood Stabilizers

Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia or Bipolar I Disorder Antipsychotics Bipolar Disorder Schizophrenia Real-World Adherence Persistence Relapse

Real-World Healthcare Utilization and Costs Associated With Using Dextromethorphan-Bupropion Extended-Release Tablets Versus Branded Comparators for the Treatment of Major Depressive Disorder Antidepressants Major Depression VA Healthcare Resource Utilization

Real-World Impact of Olanzapine and Samidorphan on Rates of Relapse Among Young Adults With Schizophrenia or Bipolar I Disorder Antipsychotics Bipolar Disorder Schizophrenia Real-World Relapse Younger Adults

Real-World Treatment Patterns and Clinical Management of Alzheimer’s Disease Agitation Acute Agitation Geriatrics Neuropsychiatric Symptoms Of Dementia Alzheimer's Disease

Reasons Patients Deprescribe Benzodiazepines in the Veteran Affairs Health System Anxiolytics VA Benzodiazepine Deprescribing

Recognition and Management of Methamphetamine-Induced Psychosis: A Focus Group Study Stimulants Substance Use Disorders Methamphetamine-Induced Psychosis

Reducing Sedative Use Through Pharmacist-Led Benzodiazepine Tapering (REST-RX) In Primary Care Anxiolytics Geriatrics Substance Use Disorders Benzodiazepine

Regulatory Challenges in Psychiatric Drug Development: Analyzing Approved Complete Response Letters Antidepressants Antipsychotics Bipolar Disorder Major Depression Schizophrenia Substance Use Disorders Regulatory Clinical Trial Pain

Remission With Lumateperone 42 mg Adjunctive to Antidepressant Therapy in Patients With Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials Bipolar Disorder Schizophrenia

Resting State Electroencephalogram (EEG)-Based, Artificial Intelligence/Machine Learning (AI/ML) Biomarker for Predicting Treatment Response in Major Depressive Disorder (MDD) Major Depression Neurology EEG Artificial Intelligence/Machine Learning Placebo Response

Retrospective Review of Buprenorphine Prescribing Practices for Persistent Pain Management at a Veterans Affairs Medical Center Education/Training/Stigma Harm Reduction Therapeutic Drug Monitoring VA Pain

Retrospective Review of Dual Long-Acting Injectable Antipsychotic Use for Treatment-Resistant Schizophrenia Adherence Antipsychotics Long-Acting Injectable Schizophrenia Transitions Of Care

Rural Evaluation of Psychiatric Pharmacy to Improve Access to Mental Health Care and Healthcare Utilization (REACH Study) Antidepressants Antipsychotics Anxiolytics Bipolar Disorder Health Equity Major Depression Post-Traumatic Stress Disorder/ PTSD Schizophrenia Sleep Disorder Transitions Of Care Mood Stabilizers

Safety and Efficacy of Aripiprazole Lauroxil in an Outpatient Setting After Initiation During Hospitalization for an Acute Exacerbation of Schizophrenia Antipsychotics Long-Acting Injectable Schizophrenia Transitions Of Care Aripiprazole Lauroxil Outpatient Safety

Spironolactone for Hormonal and Psychiatric Stabilization in Jacobs Syndrome: A Case Report Acute Agitation Bipolar Disorder Neurology Substance Use Disorders Mood Stabilizers Jacobs Syndrome Spironolactone Generalized Anxiety Disorder ADHD Elevated Testosterone

Sublingual Cyclobenzaprine for Nonrestorative Sleep in Fibromyalgia: A Scoping Review of the First FDA Approval in 15 years Neurology Sleep Disorder Fibromyalgia Nonrestorative Sleep Cyclobenzaprine Sublingual Drug Delivery Chronic Pain

Swallowing the Pain: Buprenorphine/Naloxone for Refractory Non-Suicidal Self-Injury in Borderline Personality Disorder Antipsychotics Harm Reduction Opioid Use Disorder Post-Traumatic Stress Disorder/ PTSD Borderline Personality Disorder Non-Suicidal Self-Injury

The Clozapine Initiative – Building a Sustainable Pharmacist-Led Pathway to Optimize Clozapine Utilization Antipsychotics Schizophrenia VA

The Effect of Long-Acting Injectable Buprenorphine on Healthcare Service Utilization Harm Reduction Long-Acting Injectable Opioid Use Disorder Substance Use Disorders Buprenorphine

The Effectiveness of Automated Alerts in Enhancing Lithium Monitoring Adherence Adherence Monitoring Therapeutic Drug Monitoring VA Mood Stabilizers

The Evaluation of Clozapine Access Pre- and Post-REMS Removal Antipsychotics Schizophrenia

The Impact of Seizure First Aid Training on University Students, Faculty, and Staff Education/Training/Stigma Neurology Seizures Seizure First Aid

The Switch for Sleep: Doxepin vs. Trazodone and Treatment Outcomes for Insomnia on an Inpatient Psychiatric Unit Antidepressants Sleep Disorder

Theory of Planned Behavior Assessment of Experiences and Medication Attitudes in Pharmacist-Led Education Groups Adherence Education/Training/Stigma Substance Use Disorders Group

Translating Interventions Into Outcomes: What Drives Clinical Improvement Among Patients Referred to a Psychiatric CMM Pharmacist? Comprehensive Medication Management Clinical Outcomes Psychiatric Pharmacist Interventions

Treatment-Resistant Depression: Assessing Feasibility of Centralized TRD Consultation for Somatic Therapy Referrals Major Depression Treatment-Resistant Depression

Understanding Substance Use Disorder Prescribing Practices In a State-Operated Psychiatric Hospital Alcohol Use Disorder Opioid Use Disorder Substance Use Disorders Transitions Of Care

Use of Injectable Medications for Pediatric Agitation: Comparison Across Different Levels of Care Acute Agitation Antipsychotics Child And Adolescent Psychiatry Monitoring

Use of Intramuscular Ziprasidone and Intramuscular Diphenhydramine in combination with Intramuscular Lorazepam or Intramuscular Midazolam in the Management of Acute Agitation in a Psychiatric Care Facility​ Acute Agitation Antipsychotics

Using a Needs Assessment Approach to Guide Future Development of Educational Material for Psychiatric Providers and Pharmacists on Clozapine Use and Monitoring Antipsychotics Education/Training/Stigma Monitoring Schizophrenia Therapeutic Drug Monitoring

Utilization of Extended-Release Buprenorphine at a Tertiary Medical Center Long-Acting Injectable Substance Use Disorders VA

Utilization of Methadone in the Post-COVID-19 Era Adherence Harm Reduction Opioid Use Disorder Substance Use Disorders VA

Utilization of Naloxone Nasal Spray at Discharge in Psychiatric Inpatients with Opioid Use Disorder Education/Training/Stigma Harm Reduction Health Equity Opioid Use Disorder Substance Use Disorders Transitions Of Care

Utilizing SQL-Based Data Extraction to Support Clinical Evaluation and Dashboard Development for Antipsychotic-Induced Metabolic Effects Antipsychotics Monitoring VA Metabolic

Valbenazine Improves Patient-Reported Quality of Life, Functional Impact, and Abnormal Movements of Tardive Dyskinesia: Results From the Phase 4 KINECT‑PRO™ Study Bipolar Disorder Major Depression Schizophrenia Tardive Dyskinesia Patient Reported Outcomes Quality Of Life VMAT-2 Valbenazine

Viral Infection as a Possible Modifier of Neuroleptic Malignant Syndrome: a Systematic Review Antipsychotics COVID-19 Monitoring Neuroleptic Malignant Syndrome (NMS)

“I Didn’t Know It Was Addictive”: Severe Kratom and 7- Hydroxymitragynine Dependence in a Young Adult Education/Training/Stigma Harm Reduction Monitoring Opioid Use Disorder Substance Use Disorders